2010 seminar schedule

Biodosimetry: Tools

Emergency Response Resources
Advisory team
Other resources

Guidance for Managing
Radiation Casualties
POLICIES
Depleted uranium (193-kb PDF)
Potassium iodide (106-kb PDF)
Prussian blue (124-kb PDF)
PUBLICATIONS
Emergency radiation
  medicine response (55-kb PDF)
Management of
  radiological casualties (793-kb PDF)
Plan: Response to a
  nuclear detonation (870-kb PDF)
Quick reference: NCRP
  recommendations (66-kb PDF)
Textbook: Consequences
  of nuclear warfare

Medical Effects of
Ionizing Radiation
Course description
Schedule, fees, registration
Course resources

Products: Quick List
Exposure assessment tools
Forms
Guidance
Publications
Books/book chapters
Contract reports/films
Journal articles/supplements
Reports/report chapters
Scientific reports
Special publications
Technical reports

Register AFRRI Products

Research: Programs
• Biological dosimetry
• Radiation injury combined
   with other trauma
• Internal contamination
   and metal toxicity
• Radiation countermeasures

Seminars: Schedule

USU Graduate
Education: Radiation Biology

You are here: HOME > Seminars > 2009 seminar schedule
Seminars
Jump to: 2009 \| 2008 \| 2007 \| 2006 \| 2005 \| 2004 \| 2003
Venue
Time: 11 a.m. to 12 noon (unless otherwise noted) each Friday Place: AFRRI Conference Room, unless otherwise indicated.
Directions to AFRRI \| Security, base access, parking
Seminars are presented by AFRRI researchers and other members of the scientific community. While some seminars are open to the public, others are limited to specific audiences. Any exceptions to time, place, and admittance are noted with each item. We do not record or distribute information presented in our Seminar Program. However, where available, references to related information are provided with the seminar title.
2010 seminar schedule
Friday, April 23: Ashima Saxena, PhD, Chief, Department of Structural & Molecular Biology, Division of Bacterial & Rickettsial Diseases, Walter Reed Army Institute of Research, Silver Spring, MD: Developing bioscavengers for the prophylaxis of nerve agent toxicity. Related information: Efficacy of human serum butyrylcholinesterase against sarin vapor. Chem Biol Interact. 175:267–272, 2008. Comparison of oxime reactivation and aging of nerve agent-inhibited monkey and human acetylcholinesterases. Chem Biol Interact. 175:261–266, 2008. An in vitro comparative study on the reactivation of nerve agent-inhibited guinea pig and human acetylcholinesterases by oximes. Biochemistry 46:11771–11779, 2007. Friday, April 9: Thomas B. Elliott, PhD, Research Microbiologist, Combined Injury Program, AFRRI: Combined therapy for wound infection in mixed-field-neutron-irradiated mice. Related information: Wound trauma increases radiation-induced mortality by activation of iNOS pathway and elevation of cytokine concentrations and bacterial infection. Radiat Res. 173:319–332, 2010. Combined injury: factors with potential to impact radiation dose assessments. Health Phys. 98:145–152, 2010. COX-2 inhibitors are contraindicated for treatment of combined injury. Radiat Res. 172:686–697, 2009. Friday, March 26: Gregory L. King, PhD, Research Physiologist, Biodosimetry Program, AFRRI: The prodromal phase of the ARS to varied irradiation qualities in the ferret model. Related information: 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation. Aviat Space Environ Med. 70:485–492, 1999. Plasticity of autonomic control of emesis in irradiated ferrets. Am J Physiol. 265: R1092–R1099, 1993. Characterization of radiation-induced emesis in the ferret. Radiat Res. 114:599–612, 1988. Friday, March 19: G. David Ledney, PhD, Research Biologist, Combined Injury Program, AFRRI: Combined injury: γ-photon and mixed-field irradiations, trauma, infection and selected countermeasures. Related information: Combined injury: factors with potential to impact radiation dose assessments. Health Physics 98: 145–152, 2010. Resident bacteria in a mixed population of rhesus macaque (Macaca mulatta) monkeys: a prevalence study. J Med. Primatology 38:397–403, 2009. COX-2 inhibitors are contraindicated for treatment of combined injury. Radiat Res.172:686–697, 2009. Friday, March 12: Julie L. Christensen, PhD, Group Leader-Cell Biology, Cellerant Therapeutics, San Carlos, Calif.: Development of ex vivo expanded allogeneic myeloid progenitors as a medical countermeasure for ARS. Related information: Prevention and reversal of autoimmune disease in lupus-prone NZB/NZW mice by transplantation of purified allogeneic hematopoietic stem cells. Blood 110:1370–1378, 2007. Loss of expression of the HOXA-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood 106:3988–3994, 2005. Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell 119:543–554, 2004. Friday, March 5: John F. Kalinich, PhD, Program Advisor, Internal Contamination and Metal Toxicity Program, AFRRI: Health effects of embedded metal fragments. Related information: The use of established skeletal muscle cell lines to assess potential toxicity from embedded metal fragments. Toxicology In Vitro 23:356–359, 2009. Protocol for the assessment of potential health effects from embedded metal fragments. Mil Med. 174:265–269, 2009. Urinary and serum metal levels as indicators of embedded tungsten alloy fragments. Mil Med. 173:754–758, 2008. Friday, February 26: Venkataraman Srinivasan, PhD, Research Biologist, Radiation Countermeasures Program, AFRRI: Mitochondrial metabolism and ionizing radiation: Preliminary studies. Related information: Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic, as a radiation countermeasure. Immunopharmacol Immunotoxicol. 30:271–290, 2008. Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxident gamma-tocotrienol. Life Sciences 78:2099–2104, 2006. Genistein treatment protects mice from ionizing radiation injury. J Appl Toxicol. 23:379–385, 2003. Friday, February 19: K.S. Kumar, PhD, Research Chemist, Radiation Countermeasures Program, AFRRI: Further studies on gamma-tocotrienol. Related information: Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol. 85:598–606, 2009. Radiation protection by a new chemical entity, Ex-Rad™: efficacy and mechanisms. Radiat Res. 71:173–179, 2009. Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant gamma-tocotrienol. Life Sci. 78:2099–104, 2006. Friday, February 12: Michael R. Landauer, PhD, Research Toxicologist, AFRRI: Radioprotective efficacy of genistein: Update. Related information: Effects of genistein administration on cytokine induction in whole-body gamma irradiated mice. Int Immunopharmacol. 9:1401–1410, 2009. Genistein induces radioprotection by hematopoietic stem cell quiescence. Int J Radiat Biol, 84:713–726, 2008. Genistein protects against biomarkers of delayed lung sequelae in mice surviving high-dose total body irradiation. J Radiat Res (Tokyo, 49:361–72, 2008. Friday, January 29: Mark H. Whitnall, PhD, Program Advisor, Radiation Countermeasures Program, AFRRI: Radiation countermeasure 5-androstenediol: Update. Related information: Role of NF-kappaB in hematopoietic niche function of osteoblasts after radiation injury. Exptl Hematol. 37:52–64, 2009 Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 30:271–290, 2008. Administration of 5-androstenediol to mice: pharmacokinetics and cytokine gene expression. Exp Mol Pathol. 84:178–188, 2008. Friday, January 15: Shilpa Kulkarni, PhD, Research Associate, Henry M. Jackson Foundation (Radiation Countermeasures Program, AFRRI): Radioprotective efficacy and molecular mechanisms of gamma tocotrienol alone and in combination with pentoxifylline. Related information: Gamma-tocotrienol, a tocol antioxidant as a potent radiation radioprotector. Intl J Rad Biol. 85:598–606, 2009. Radiation protection by a new chemical entity Ex-Rad™: efficacy and mechanisms. Radiation Research 171:173–179, 2009. Molecular basis for specific sub-cellular localization of C2 like domain of 5 lipoxygenase. J Biol Chem. 277:13167–74, 2002. Friday, January 8: Risaku Fukumoto, PhD, Research Associate, Henry M. Jackson Foundation (Radiation Combined Injury Program, AFRRI): 17-DMAG: A heat shock protein inhibitor as a potential candidate in radioprotection. Related information: In vivo genetic mutations define predominant functions of the human T-cell Leukemia/Lymphoma Virus p12I protein. Bloo, 113:3726-3734, 2009. Inhibition of TCR signal transduction and viral expression by the linker for activation of T cells–interacting p12(I)protein of HTLV-1. J. Virol. 81:9088-9099, 2007. HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med. 10:197-201, 2004.
TOP OF PAGE


USU site index \| USU home			AFRRI home \| Text version \| A-Z Index
No Fear Act \| Privacy/Security notice			RSS feeds \| Disclaimer \| Copyright